Necmi Eren
Overview
Explore the profile of Necmi Eren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barratt J, Barbour S, Brenner R, Cooper K, Wei X, Eren N, et al.
J Am Soc Nephrol
. 2024 Oct;
PMID: 39462308
No abstract available.
2.
Mirioglu S, Cebeci E, Yazici H, Derici U, Sahin G, Coban G, et al.
Clin Kidney J
. 2024 Oct;
17(8):sfae077.
PMID: 39421234
Background: Data on the prognostic factors for C3 glomerulopathy (C3G) are limited, and validation of the new C3G histologic index (C3G-HI) in different settings is still needed. We aimed to...
3.
Artan A, Mirioglu S, Hocaoglu R, Turgutalp K, Gullulu Boz S, Eren N, et al.
BMC Nephrol
. 2024 Oct;
25(1):327.
PMID: 39354386
Background: We evaluated the efficacy of different immunosuppressive regimens in patients with primary membranous nephropathy in a large national cohort. Methods: In this registry study, 558 patients from 47 centers...
4.
Gungor O, Dheir H, Islam M, Toz H, Yildiz A, Sinangil A, et al.
Clin Nephrol
. 2024 Jul;
102(4):202-211.
PMID: 39037084
Aim: BK polyomavirus infection is a challenging complication of renal transplantation. The management is not standardized and is based on reports from transplantation centers' experiences, usually with small sample sizes....
5.
Oruc A, Sumnu A, Turkmen A, Basturk T, Cebeci E, Turgutalp K, et al.
Ren Fail
. 2024 Apr;
46(1):2341787.
PMID: 38637275
Background: Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate...
6.
Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al.
Kidney Int
. 2024 Mar;
105(6):1306-1315.
PMID: 38552841
Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in...
7.
Kurultak I, Gungor O, Ozturk S, Dirim A, Eren N, Yenigun E, et al.
Sci Rep
. 2024 Mar;
14(1):6748.
PMID: 38514826
The data regarding primary FSGS (pFSGS) from different parts of the world differ. While the prevalence of pFSGS has been increasing in Western countries like the USA, it follows an...
8.
Cetinkaya H, Gursu M, Yazici H, Cebeci E, Eren N, Altiparmak M, et al.
J Nephrol
. 2023 Nov;
37(4):923-932.
PMID: 37947938
Background: Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephropathy. There is evidence that mesangial C3 deposition plays a role in the development of the disease. The aim of this...
9.
Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, et al.
Lancet
. 2023 Aug;
402(10405):859-870.
PMID: 37591292
Background: IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is...
10.
Bek S, Yildiz N, Islam M, Ergul M, Sarioglu I, Guven Taymez D, et al.
Clin Exp Nephrol
. 2023 Jul;
27(10):828.
PMID: 37428290
No abstract available.